Seagen highlights first solid tumor data for an adcetris® (brentuximab vedotin) immunotherapy combination and preclinical data for novel cd30-directed antibody-drug conjugate at society for immunotherapy of cancer (sitc) annual meeting

Bothell, wash.--(business wire)--seagen inc. (nasdaq: sgen) today announced the first presentation of data evaluating adcetris® (brentuximab vedotin) in combination with an anti-pd-1 checkpoint inhibitor in non-small cell lung cancer (nsclc) and melanoma, and shared preclinical data for an investigational cd30-directed antibody-drug conjugate (adc) that uses a novel tripeptide linker. the studies were presented at the society for immunotherapy of cancer (sitc) 38th annual meeting, taking place.
SGEN Ratings Summary
SGEN Quant Ranking